Immunotherapies for Alzheimer’s disease
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antibodies targeting amyloid-β aggregates slow decline in Alzheimer’s disease
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All three have shown efficacy in clearing Aβ plaque and slowing cognitive decline, but the risks of amyloid-related imaging abnormalities (ARIA) and their treatment costs are noteworthy.422–424”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [422]
Citations
Cites
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Self-citationSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Söderberg, L., Johannesson, M., Nygren, P., Laudon, H., Eriksson, F., Osswald, G., Möller, C., & Lannfelt, L. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01308-6 · Cited by 427
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H., Cummings, J., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 327
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke
Reish, N. J., Jamshidi, P., Stamm, B., Flanagan, M. E., Sugg, E., Tang, M., Donohue, K. L., McCord, M., Krumpelman, C., Mesulam, M.-M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2215148 · Cited by 232
Alzheimer's disease: The right drug, the right time
Golde, T. E., DeKosky, S. T., & Galasko, D. (2018) · Science · doi:10.1126/science.aau0437 · Cited by 147
Self-citation
Research works printed but not linked: 1
- S. Budd Haeberlein , J. Prev. Alzheimers Dis. 9, 197 (2022).
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Cell-type-directed network-correcting combination therapy for Alzheimer’s disease
Li, Y., Serras, C. P., Blumenfeld, J. R., Xie, M., Hao, Y., Deng, E., Chun, Y. Y., Holtzman, J., An, A., Yoon, S. Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.035 · Cited by 74
Amyloid-β-targeting immunotherapies for Alzheimer's disease
Jin, Y., Du, Q., Song, M., Kang, R., Zhou, J., Zhang, H., & Ding, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.012 · Cited by 65
Greenberg, S. M., & van Veluw, S. J. (2024) · Stroke · doi:10.1161/strokeaha.124.044293 · Cited by 32
Fang, S., Zhang, K., Liu, D., Yang, Y., Hu, X., Xie, W., Diao, K., Rao, Z., Wang, D., & Yang, W. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1408620 · Cited by 29
“During the past two decades, the primary therapeutic approaches for AD have encompassed interventions targeting anti-neurotoxic β -amyloid (A β ) aggregates, anti-Tau, anti-neuroinflammatory, neuroprotective agents, and brain stimulation, among others (2–4).”
Backgroundα-Synuclein pathology and mitochondrial dysfunction: Toxic partners in Parkinson's disease
Mingo, Y. B., Galvis, M. L. E., & Henderson, M. X. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106889 · Cited by 31
Morasso, C., Truffi, M., Tinelli, V., Stivaktakis, P. D., Gerlando, R. D., Dragoni, F., Perini, G., Faisal, M., Aid, J., Noridov, B., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02897-4 · Cited by 34
“Despite the advent of new immune-based therapies, current treat-ment are not curative and their relevance to the millions of AD patients worldwide remain unclear [1].”
Current state and perspectives of CAR T cell therapy in central nervous system diseases
Pfeffer, L. K., Fischbach, F., Heesen, C., & Friese, M. A. (2024) · Brain · doi:10.1093/brain/awae362 · Cited by 21
Roflumilast and cognition enhancement: A translational perspective
Prickaerts, J., Kerckhoffs, J., Possemis, N., van Overveld, W., Verbeek, F., Grooters, T., Sambeth, A., & Blokland, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117707 · Cited by 21
Fagla, B. M., & Buhimschi, I. A. (2024) · Molecules · doi:10.3390/molecules29030610 · Cited by 18
“Importantly, after decades of pre-clinical development and many clinical failures, immunotherapy approaches for the treatment of AD have finally shown success in phase-three clinical trials [232].”
BackgroundTau, synapse loss and gliosis progress in an Alzheimer’s mouse model after amyloid-β immunotherapy
Welikovitch, L. A., de Gérando, A. M., Khasnavis, A., Bhavsar, H., Meltzer, J. C., Buée, L., Chibnik, L. B., Bussière, T., & Hyman, B. T. (2024) · Brain · doi:10.1093/brain/awae345 · Cited by 18
Neuroinflammation and nutrition in Alzheimer’s disease
Park, H., Ni, M., & Le, Y. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1622571 · Cited by 17
“…development, such as small molecules (e.g., glutamate modulators, acetylcholinesterase inhibitors) to improve synaptic function and immunotherapy (e.g., anti-A β : lecanemab, donanemab, or anti-β / γ -secretases) to remove plaques and reduce tau tangles, but have had modest success (7, 8, 86, 87).”
Jicha, G. A., Abner, E. L., Coskun, E. P., Huffmyer, M. J., Tucker, T. C., & Nelson, P. T. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12500 · Cited by 13
Improving Alzheimer’s disease immunotherapy
Xing, M., & Song, W. (2025) · Science · doi:10.1126/science.adz8959 · Cited by 18
Liang, C., Paclibar, C. G., Gonzaga, N. L., Sison, S. A., Bath, H. S., Biju, A. P., & Mukherjee, J. (2024) · Neurology International · doi:10.3390/neurolint16020031 · Cited by 11
“Lecanemab and Aducanumab are both of current interest due to their promising efficacy in early-stage Alzheimer’s disease [22], despite a few reports of amyloid-related imaging abnormalities (ARIA) [23].”
BackgroundKang, J. M., Kim, N., Yun, S. K., Seo, H., Bae, J. N., Kim, W., Na, K., Cho, S., Ryu, S., Noh, Y., et al. (2024) · Psychogeriatrics · doi:10.1111/psyg.13161 · Cited by 13
“1 Although disease-modifying immunotherapy offers new treat-ment avenues, 2 preventing dementia and mitigating risk factors remain paramount.”
Eid, F., Boushehri, M., Boucher, C., Rajkanth, N., Sa, A. F., Alhoutan, T., Vavetsi, K., Dibart, S., & Ma, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202403117rr · Cited by 10
Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00573-1 · Cited by 11
“All are human or humanized IgG monoclonal antibodies against Aß aimed to neutralize Aß levels in the brain and have been shown to slow cognitive and functional decline in early AD [64, 65].”
BackgroundLin, H.-C., & Lane, H. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03492-3 · Cited by 9
“In addition to the key role of A β in the pathogenesis of AD, other factors, including oxidative stress, may contribute to AD [2, 6, 13, 14, 36 – 38].”
Cerebral Amyloid Angiopathy: Clinical Presentation, Sequelae and Neuroimaging Features—An Update
Weidauer, S., & Hattingen, E. (2025) · Biomedicines · doi:10.3390/biomedicines13030603 · Cited by 12
Bai, S., Wang, Y., Ye, W.-L., Wu, S.-Y., Jia, L., Hong, L., Xie, H., & Gao, L. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01587-y · Cited by 9
“Considering the potential side effects 13 and relatively high cost 10 of antibody therapies, developing inhibitors for A β aggregation seems to be a safer and more affordable alternative for AD treatment.”
Longo, S., Messi, M. L., Wang, Z., Meeker, W. Q., & Delbono, O. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13482 · Cited by 9
“22”
Jicha, G. A., Tucker, T. C., Arnold, S. M., & Nelson, P. T. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01532-6 · Cited by 7
“The partial success of Aβ immunotherapies, and the controversy surrounding their use, only increases the urgency for data-driven discussions in the field [3].”
BackgroundZhu, Q., Song, Y., Qian, Y., Zhang, R., Xue, J., & Hou, Y. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.25 · Cited by 10
Park, S., Shahapal, A., Yoo, S., Kwak, H., Lee, M., Lee, S., Hwang, J., & Seong, J. Y. (2024) · Experimental Neurobiology · doi:10.5607/en24017 · Cited by 6
Liu, F.-X., Yang, S.-Z., Shi, K.-K., Li, D., Song, J.-B., Sun, L., Dang, X., Li, J., Deng, Z.-Q., Zhao, M., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1540019 · Cited by 11
“The primary features of the disease include the formation of amyloid beta (A β ) protein plaques and the over phosphorylation and aggregation of tau, ultimately leading to neurofibrillary tangles (NFTs) (Golde and Levey, 2023).”
Cui, W., Wang, Y., Tang, X., Liu, S., Duan, Y., Gu, T., Mao, J., Li, W., Bao, J., & Wei, Z. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136477 · Cited by 8
Zhang, Z., Lv, M., Xu, J., Liu, Y., Qin, J., Fan, Z., & Du, J. (2025) · JACS Au · doi:10.1021/jacsau.5c00721 · Cited by 7
Huang, Q., Lv, Y. M., Ye, X. W., Xia, X., Chen, Y., Wang, X., Tong, F., Yang, W., Bozorov, K. A., Shevtsov, M. A., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114896 · Cited by 9
Counts, S., Beck, J. S., Maloney, B., Malek‐Ahmadi, M. H., Ginsberg, S. D., Mufson, E. J., & Lahiri, D. K. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70019 · Cited by 7
Chang, S., Ding, N., Li, Y., Li, Y., Tang, Z., Pan, J., Li, Y., & Chen, J. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70349 · Cited by 5
Tang, Y., Wang, Y., Gao, Z., Li, J., Zhang, L., Shi, H., Dong, J., Song, S., & Qian, C. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202400870 · Cited by 7
A deeper dive into amyloid clearance by meningeal lymphatic vessels
Santisteban, M. M., & Iadecola, C. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00427-x · Cited by 4
Kuang, X. C., Rempel, D. L., Lin, Y., & Gross, M. L. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00033 · Cited by 4
Inhibiting the Aggregation of Aβ by Natural Product Molecules
Bai, S., Wang, Y., Li, X., & Gao, L. (2024) · ChemMedChem · doi:10.1002/cmdc.202400223 · Cited by 4
Li, Y., Serras, C. P., Blumenfeld, J. R., Xie, M., Hao, Y., Deng, E., Chun, Y. Y., Holtzman, J., An, A., Yoon, S. Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.09.627436 · Cited by 3
Wang, Y., Bai, S., Hu, X., Lin, J., Ye, W.-L., Xie, H., Hong, L., & Gao, L. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.114032 · Cited by 4
Gupta, D. K., & Chaudhuri, A. (2025) · CHRISMED Journal of Health and Research · doi:10.4103/cjhr.cjhr_48_25 · Cited by 2
Traditional Chinese medicine: a promising whole-process management for Alzheimer’s disease
Yao, L., Ni, J., Wei, M., Li, T., Li, F., Shi, J., & Tian, J. (2026) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000209 · Cited by 2
Mimicking the structure and function of tau folds associated with disease
Schymkowitz, J. W. H., & Rousseau, F. (2025) · Nature Chemistry · doi:10.1038/s41557-025-01841-9 · Cited by 1
Sun, R., Wang, X., Wang, Z., Li, C., Shao, Q., Liu, X., Zhu, H., Wang, S., & He, K. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70833 · Cited by 1
“…have demonstrated limited efficacy in symptom alleviation or in decelerating disease progression, thereby highlighting the pressing need for a comprehensive understanding of the underlying patho-physiological mechanisms and discovering novel biomarkers for early diagnosis and intervention [4, 5].”
Zhang, Z., Lv, M., Hu, W., Xu, J., Liu, S., Yang, B., Zhang, F., & Fan, Z. (2026) · Advanced Functional Materials · doi:10.1002/adfm.202529220 · Cited by 1
“However, inexact progression from A β to actual dementia and undesirable side effects of existing clinical implementations still remain [6].”
Vaccination strategies in neurodegenerative proteinopathies
Tao, C., Zhao, D., & Yang, L. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103337 · Cited by 1
A Novel Oxo‐Palmatine Derivative 2q as Potent Reversal Agents Against Alzheimer's Disease
Pang, S., Li, Z., Liu, A., Luo, Z., Yin, H., Fan, S., Shi, J., Liu, N., Pan, S., Yang, Y., et al. (2025) · Drug Development Research · doi:10.1002/ddr.70073 · Cited by 1
“Although all three drugs have demonstrated efficacy in clearing beta ‐ amyloid plaques and slowing cognitive decline, concerns regarding the risks of amyloid ‐ related imaging abnormalities (ARIA) and their overall therapeutic efficacy persist (Couzin ‐ Frankel 2023; Golde and Levey 2023).”
Paterno, G., Moore, B. D., Bell, B. M., Gorion, K.-M. M., Ran, Y., Prokop, S., Golde, T. E., & Giasson, B. I. (2024) · Antibodies · doi:10.3390/antib13030068
“Antibodies used in clinical trials have been assessed for their abilities to engage distinct A β species [44] but also have shown diverse clinical outcomes [45–52].”
BackgroundSelf-citationNew Progress in the Treatment of Alzheimer’s Disease
朱, 玉. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1561810
Feuerbach, A., & Skerra, A. (2025) · Protein Engineering Design and Selection · doi:10.1093/protein/gzaf012
Hong, Y., Shu, W., Wang, Y., Wang, Y., Jiang, J., Jin, G., Chen, H., & Фу, Л. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.10.17 · Cited by 1
“38,46,47 Additionally, immunocyte phenotypes can serve as biomarkers for predicting disease risk, progression, or response to treatment.”
Anti-inflammatory and immunomodulating agents
Britten, J. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00014-4
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049039
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049054
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049060
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049048
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049051
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049045
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049063
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049042
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049057
New Insights into Drug Development and Immunotherapy for Alzheimer’s Disease
Gayen, S., Roy, S., Uddin, M. A., & Sukul, D. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010014
Pal, T., Mukherjee, S., Karati, D., Pahari, N., Hossain, C. M., & Naskar, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010017
An ER stress-responsive RNA rheostat for programmable gene and mRNA therapies
Ogurlu, R., Sanchez, E. B., Hull, J. A., Fergione, S., Yudistyra, V., Webb, G. M., Wu, H. L., Pessoa, C. T., Humkey, M. C., Potter, S. K., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.07.006
Hong, E., 박성민, Lin, Y., Kwak, J., Lee, Y.-H., & Lim, M. H. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103563
Discriminating Monomers and Fibrils of Amyloid‐ β 1–42 With Site‐Ordered Peptide‐QMFluors
Dai, R., Dai, J., Yan, C., Shi, L., Bi, J., Huang, P., Zhai, Y., Sun, S., Zhu, W., & Guo, Z. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.3711838
Discriminating Monomers and Fibrils of Amyloid‐ β 1–42 With Site‐Ordered Peptide‐QMFluors
Dai, R., Dai, J., Yan, C., Shi, L., Bi, J., Huang, P., Zhai, Y., Sun, S., Zhu, W., & Guo, Z. (2026) · Angewandte Chemie · doi:10.1002/ange.3711838
Neuroimmune phenotypes in brain aneurysms and neurodegenerative diseases
Lauzier, F. J., & Lauzier, D. C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1916561
“…has been used with success in several classes of neurological diseases, targeted investigation into neurovascular inflammation may unveil new avenues of experimental targeting that can be eventually translated into the clinical setting (Golde and Levey, 2023; Bourque and Hawiger, 2021).”
A cell-type-directed drug repurposing framework for Alzheimer's disease subtypes
Li, Y., Tang, X., Serras, C. P., Tang, A., Oskotsky, T., & Sirota, M. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.10.019
Metadata
- Authors
- Golde, T. E., & Levey, A. I.
- Affiliations
- Emory University (US)
- Venue
- Science
- Published
- 2023-12-15
- Volume
- 382
- Issue
- 6676
- Pages
- 1242-1244
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4389764088
- Cited by
- 66
- References
- 14
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 31
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, immunotherapy, amyloid-beta, anti-amyloid antibodies, amyloid-beta aggregates, cognitive decline
- MeSH terms
- Alzheimer Disease, Antibodies, Clinical Trials as Topic, Humans, Immunotherapy, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.